Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Addex awarded MJFF grant to develop treatment for Parkinsonís symptoms
October 2010
SHARING OPTIONS:

GENEVA, SwitzerlandóAllosteric modulation company Addex Pharmaceuticals Ltd. recently announced that it has been awarded a $900,000 grant from the Michael J. Fox Foundation (MJFF) to help fund a Phase II study of ADX48621 for the treatment of Parkinson's disease (PD) levodopa-induced dyskinesia (LID), a leading cause of disability in this growing patient population. ADX48621 is a metabotropic glutamate receptor 5 negative allosteric modulator (NAM). It already has successfully completed Phase I testing in three studies involving a total of 130 patients, including older healthy volunteers. A Phase II study of ADX48621 to treat PD-LID is expected to start in the United States and Europe during the fourth quarter.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.